Novartis Fabhalta Gains FDA Approval For Primary IgAN In 2026
FDA decision expands the Fabhalta indication from reducing proteinuria to slowing kidney function decline in adults at risk of disease progression. BASEL, Switzerland, July 17, 2026 – Novartis has announced that the U.S. Food and Drug Administration has granted traditional approval to Fabhalta® (iptacopan) for slowing kidney function decline in adults with primary immunoglobulin A … Read more
